Wolfgang Oster to chair Formula
This article was originally published in Scrip
Privately-held oncology drug development company Formula Pharmaceuticals has appointed Dr Wolfgang Oster chair of the board. Dr Oster is managing partner for life science at Polytechnos Venture-Partners and an active entrepreneur. He is also a board member of Cappella, Intelligent Medical Implants, ImmunoGenes, Hemacon, Oncoceutics, Provid, Noblegen and Genossis.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.